vs
ONITY GROUP INC.（ONIT）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
ONITY GROUP INC.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.4倍（$290.0M vs $207.3M），ONITY GROUP INC.净利率更高（43.9% vs -62.0%，领先105.9%），ONITY GROUP INC.同比增速更快（29.0% vs 25.9%），Ultragenyx Pharmaceutical Inc.自由现金流更多（$-100.8M vs $-750.9M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 10.1%）
奥尼提集团（原奥克文）是一家提供住宅及商业抵押贷款 servicing、特殊 servicing以及资产管理服务的供应商，业务性质也可概括为向房主收取每月本金与利息。公司成立于1988年，总部位于佛罗里达州西棕榈滩，在美国多地及菲律宾、印度都设有办公及支持运营点。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
ONIT vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $290.0M | $207.3M |
| 净利润 | $127.2M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | — | -54.7% |
| 净利率 | 43.9% | -62.0% |
| 营收同比 | 29.0% | 25.9% |
| 净利润同比 | 552.7% | 3.5% |
| 每股收益（稀释后） | $14.53 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $290.0M | $207.3M | ||
| Q3 25 | $280.3M | $159.9M | ||
| Q2 25 | $246.6M | $166.5M | ||
| Q1 25 | $249.8M | $139.3M | ||
| Q4 24 | $224.8M | $164.6M | ||
| Q3 24 | $265.7M | $139.5M | ||
| Q2 24 | $246.4M | $147.0M | ||
| Q1 24 | $239.1M | $108.8M |
| Q4 25 | $127.2M | $-128.6M | ||
| Q3 25 | $18.7M | $-180.4M | ||
| Q2 25 | $21.5M | $-115.0M | ||
| Q1 25 | $22.1M | $-151.1M | ||
| Q4 24 | $-28.1M | $-133.2M | ||
| Q3 24 | $21.4M | $-133.5M | ||
| Q2 24 | $10.5M | $-131.6M | ||
| Q1 24 | $30.1M | $-170.7M |
| Q4 25 | — | -54.7% | ||
| Q3 25 | — | -106.9% | ||
| Q2 25 | — | -64.8% | ||
| Q1 25 | 3.6% | -102.6% | ||
| Q4 24 | -14.9% | -74.3% | ||
| Q3 24 | 10.4% | -94.6% | ||
| Q2 24 | 5.5% | -79.1% | ||
| Q1 24 | 13.3% | -151.9% |
| Q4 25 | 43.9% | -62.0% | ||
| Q3 25 | 6.7% | -112.8% | ||
| Q2 25 | 8.7% | -69.0% | ||
| Q1 25 | 8.8% | -108.5% | ||
| Q4 24 | -12.5% | -80.9% | ||
| Q3 24 | 8.1% | -95.7% | ||
| Q2 24 | 4.3% | -89.5% | ||
| Q1 24 | 12.6% | -156.8% |
| Q4 25 | $14.53 | $-1.28 | ||
| Q3 25 | $2.03 | $-1.81 | ||
| Q2 25 | $2.40 | $-1.17 | ||
| Q1 25 | $2.50 | $-1.57 | ||
| Q4 24 | $-3.59 | $-1.34 | ||
| Q3 24 | $2.65 | $-1.40 | ||
| Q2 24 | $1.33 | $-1.52 | ||
| Q1 24 | $3.74 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $180.5M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $627.9M | $-80.0M |
| 总资产 | $16.2B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $180.5M | $421.0M | ||
| Q3 25 | $172.8M | $202.5M | ||
| Q2 25 | $194.3M | $176.3M | ||
| Q1 25 | $178.0M | $127.1M | ||
| Q4 24 | $184.8M | $174.0M | ||
| Q3 24 | $201.6M | $150.6M | ||
| Q2 24 | $203.1M | $480.7M | ||
| Q1 24 | $185.1M | $112.3M |
| Q4 25 | $627.9M | $-80.0M | ||
| Q3 25 | $501.4M | $9.2M | ||
| Q2 25 | $481.9M | $151.3M | ||
| Q1 25 | $460.2M | $144.2M | ||
| Q4 24 | $442.9M | $255.0M | ||
| Q3 24 | $468.2M | $346.8M | ||
| Q2 24 | $446.2M | $432.4M | ||
| Q1 24 | $432.1M | $140.3M |
| Q4 25 | $16.2B | $1.5B | ||
| Q3 25 | $16.1B | $1.2B | ||
| Q2 25 | $16.5B | $1.3B | ||
| Q1 25 | $16.3B | $1.3B | ||
| Q4 24 | $16.4B | $1.5B | ||
| Q3 24 | $13.2B | $1.5B | ||
| Q2 24 | $13.1B | $1.6B | ||
| Q1 24 | $13.1B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-748.0M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $-750.9M | $-100.8M |
| 自由现金流率自由现金流/营收 | -258.9% | -48.6% |
| 资本支出强度资本支出/营收 | 1.0% | 0.5% |
| 现金转化率经营现金流/净利润 | -5.88× | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $-748.0M | $-99.8M | ||
| Q3 25 | $229.5M | $-91.4M | ||
| Q2 25 | $-598.8M | $-108.3M | ||
| Q1 25 | $-148.1M | $-166.5M | ||
| Q4 24 | $-573.8M | $-79.3M | ||
| Q3 24 | $19.2M | $-67.0M | ||
| Q2 24 | $-77.9M | $-77.0M | ||
| Q1 24 | $-297.1M | $-190.7M |
| Q4 25 | $-750.9M | $-100.8M | ||
| Q3 25 | $228.8M | $-92.7M | ||
| Q2 25 | — | $-110.7M | ||
| Q1 25 | $-148.4M | $-167.8M | ||
| Q4 24 | $-574.6M | $-79.5M | ||
| Q3 24 | $19.1M | $-68.6M | ||
| Q2 24 | $-78.0M | $-79.0M | ||
| Q1 24 | $-297.2M | $-193.9M |
| Q4 25 | -258.9% | -48.6% | ||
| Q3 25 | 81.6% | -58.0% | ||
| Q2 25 | — | -66.5% | ||
| Q1 25 | -59.4% | -120.5% | ||
| Q4 24 | -255.6% | -48.3% | ||
| Q3 24 | 7.2% | -49.2% | ||
| Q2 24 | -31.7% | -53.7% | ||
| Q1 24 | -124.3% | -178.2% |
| Q4 25 | 1.0% | 0.5% | ||
| Q3 25 | 0.2% | 0.8% | ||
| Q2 25 | 0.0% | 1.5% | ||
| Q1 25 | 0.1% | 1.0% | ||
| Q4 24 | 0.4% | 0.1% | ||
| Q3 24 | 0.0% | 1.2% | ||
| Q2 24 | 0.0% | 1.4% | ||
| Q1 24 | 0.0% | 3.0% |
| Q4 25 | -5.88× | — | ||
| Q3 25 | 12.27× | — | ||
| Q2 25 | -27.85× | — | ||
| Q1 25 | -6.70× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.90× | — | ||
| Q2 24 | -7.42× | — | ||
| Q1 24 | -9.87× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ONIT
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
